ロード中...
Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies: A NARCOMS Analysis
Background: Physicians must weigh the benefits against the risk of progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab, especially beyond 2 years. However, disability progression associated with switching therapies versus continuing natalizumab therapy after 2 years...
保存先:
| 出版年: | Int J MS Care |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
The Consortium of Multiple Sclerosis Centers
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5087578/ https://ncbi.nlm.nih.gov/pubmed/27803638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7224/1537-2073.2014-113 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|